We are live on
!
Find out more
Lyell Immunopharma
LYEL
LYEL
93 hedge funds and large institutions have $404M invested in Lyell Immunopharma in 2022 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 33 increasing their positions, 18 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
586% more call options, than puts
Call options by funds: $48K | Put options by funds: $7K
83% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 18
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
0.07% more ownership
Funds ownership: 2.27% → 2.34% (+0.07%)
0% more funds holding
Funds holding: 93 → 93 (0)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
51% less capital invested
Capital invested by funds: $823M → $404M (-$419M)
Holders
93
Holders Change
–
Holders Change %
0%
% of All Funds
1.49%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.05%
New
15
Increased
33
Reduced
18
Closed
14
Calls
$48K
Puts
$7K
Net Calls
+$41K
Net Calls Change
+$26K
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$16.7M |
| 2 |
Goldman Sachs
New York
|
+$4.11M |
| 3 |
BlackRock
New York
|
+$2.19M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.95M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.94M |
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.61M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$1.27M |
| 4 |
KHCM
Kettle Hill Capital Management
New York
|
-$1.16M |
| 5 |
Morgan Stanley
New York
|
-$974K |
